keyword
MENU ▼
Read by QxMD icon Read
search

EBMT

keyword
https://www.readbyqxmd.com/read/29128085/-hla-coding-in-promise-guidelines-from-the-francophone-society-of-bone-marrow-transplantation-and-cellular-therapy-sfgm-tc
#1
Nicole Raus, Catherine Faucher, Anne Kennel, Maguy Pereira, Cécile Veron, Ibrahim Yakoub-Agha, Pascale Loiseau
As part of the 7th Annual francophone workshop series on the harmonization of clinical practices in allogeneic stem cell transplantation held in Lille in September 2016, our workgroup discussed how transplant centers might follow a collective approach to coding data. This was done mainly by analyzing the study results found in the literature that do not provide clear answers. In addition, we discuss practical ways of coding for both donor and recipient HLA typing in the European bone marrow transplantation database called ProMISe which is managed by the European Society for Blood and Marrow Transplantation (EBMT)...
November 8, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/29094350/transplant-results-in-adults-with-fanconi-anaemia
#2
Marc Bierings, Carmem Bonfim, Regis Peffault De Latour, Mahmoud Aljurf, Parinda A Mehta, Cora Knol, Farid Boulad, Abdelghani Tbakhi, Albert Esquirol, Grant McQuaker, Gulsan A Sucak, Tarek B Othman, Constantijn J M Halkes, Ben Carpenter, Dietger Niederwieser, Marco Zecca, Nicolaus Kröger, Mauricette Michallet, Antonio M Risitano, Gerhard Ehninger, Raphael Porcher, Carlo Dufour
The outcomes of adult patients transplanted for Fanconi anaemia (FA) have not been well described. We retrospectively analysed 199 adult patients with FA transplanted between 1991 and 2014. Patients were a median of 16 years of age when diagnosed with FA, and underwent transplantation at a median age of 23 years. Time between diagnosis and transplant was shortest (median 2 years) in those patients who had a human leucocyte antigen identical sibling donor. Fifty four percent of patients had bone marrow (BM) failure at transplantation and 46% had clonal disease (34% myelodysplasia, 12% acute leukaemia)...
November 2, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28977716/occurrence-of-graft-versus-host-disease-increases-mortality-after-umbilical-cord-blood-transplantation-for-acute-myeloid-leukemia-a-report-from-eurocord-and-the-alwp-of-the-ebmt
#3
Frédéric Baron, Annalisa Ruggeri, Eric Beohou, Myriam Labopin, Mohamad Mohty, Jaime Sanz, Stephane Vigouroux, Sabine Furst, Alberto Bosi, Patrice Chevallier, Jan J Cornelissen, Mauricette Michallet, Jorge Sierra, Dimitrios Karakasis, Bipin N Savani, Eliane Gluckman, Arnon Nagler
BACKGROUND: The efficacy of umbilical cord blood transplantation (UCBT) as treatment for acute myeloid leukemia (AML) relies on immune-mediated graft-versus-leukemia effects. Previous studies have suggested a strong association between graft-versus-host disease (GVHD) occurrence and graft-versus-leukemia effects after allogeneic hematopoietic cell transplantation. METHODS: Here, we evaluated the kinetics of relapse rate in correlation to GVHD occurrence after UCBT...
October 4, 2017: Journal of Internal Medicine
https://www.readbyqxmd.com/read/28971902/mixed-phenotype-acute-leukemia-outcomes-with-allogeneic-stem-cell-transplantation-a-retrospective-study-from-the-acute-leukemia-working-party-of-the-ebmt
#4
Reinhold Munker, Myriam Labopin, Jordi Esteve, Christoph Schmid, Mohamad Mohty, Arnon Nagler
Mixed phenotype acute leukemias are infrequent and considered high-risk. The optimal treatment approach and the role of allogeneic hematopoietic stem cell transplantation are not entirely clear. In this study, we investigated 519 patients with mixed phenotype acute leukemia in first complete remission who underwent allogeneic hematopoietic stem cell transplantation between 2000 and 2014 and were reported to the Acute Leukemia Working Party of the EBMT. The median age was 38.1 years (range 18- 75), by cytogenetics, 49...
September 29, 2017: Haematologica
https://www.readbyqxmd.com/read/28971504/relatively-favourable-outcome-after-allogeneic-stem-cell-transplantation-for-bcr-abl1-positive-aml-a-survey-from-the-acute-leukemia-working-party-of-the-european-society-for-blood-and-marrow-transplantation-ebmt
#5
Vladimir Lj Lazarevic, Myriam Labopin, Depei Wu, Ibrahim Yakoub-Agha, Anne Huynh, Per Ljungman, Nicolaas Schaap, Jan J Cornelissen, Natacha Maillard, Pietro Pioltelli, Tobias Gedde-Dahl, Stig Lenhoff, Mohamed Houhou, Jordi Esteve, Mohamad Mohty, Arnon Nagler
The aim of the study was to assess the role of allogeneic stem cell transplantation (SCT) in patients diagnosed with BCR-ABL1-positive acute myeloid leukemia (AML). Fifty-seven patients (median age, 48 years, range: 19-67) with BCR-ABL1 positive AML undergoing SCT were identified. The majority of the patients (70%) received a TKI before the transplant. At SCT 48 patients were in CR (45 in CR1), while 9 patients were transplanted in a more advanced stage of the disease. MRD was negative (BCR-ABL1/ABL<10(4) ) at time of SCT in 36...
October 3, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28971503/high-dose-chemotherapy-and-autologous-stem-cell-transplantation-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-retrospective-study-by-the-european-society-for-blood-and-marrow-transplantation-lymphoma-working-party
#6
Saad Akhtar, Silvia Montoto, Ariane Boumendil, Herve Finel, Tamas Masszi, Pavel Jindra, Damir Nemet, Stephan Fuhrmann, Yves Beguin, Luca Castagna, Felicetto Ferrara, Saveria Capria, Ram Malladi, Jose Maria Moraleda, Adrian Bloor, Hervé Ghesquières, Julia Meissner, Anna Sureda, Peter Dreger
Whilst autologous stem cell transplantation (auto-SCT) is considered standard of care for relapsed/refractory classical Hodgkin lymphoma, the role of auto-SCT in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is not well defined due to limited data. We report the first study on auto-SCT for NLPHL with a larger cohort. Eligible for this retrospective registry study were patients reported to the EBMT between 2003 and 2013, aged 18 or older with relapsed/refractory NLPHL who underwent first auto-SCT with disease chemosensitive to salvage therapy...
October 3, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28939455/neurocognitive-dysfunction-in-hematopoietic-cell-transplant-recipients-expert-review-from-the-late-effects-and-quality-of-life-working-committee-of-the-center-for-international-blood-and-marrow-transplant-research-and-complications-and-quality-of-life-working
#7
REVIEW
Debra Lynch Kelly, David Buchbinder, Rafael F Duarte, Jeffrey J Auletta, Neel Bhatt, Michael Byrne, Melissa Gabriel, Anuj Mahindra, Maxim Norkin, Helene Schoemans, Ami J Shah, Ibrahim Ahmed, Yoshiko Atsuta, Grzegorz W Basak, Sara Beattie, Sita Bhella, Christopher Bredeson, Nancy Bunin, Jignesh Dalal, Andrew Daly, James Gajewski, Robert Peter Gale, John Galvin, Mehdi Hamadani, Robert J Hayashi, Kehinde Adekola, Jason Law, Catherine J Lee, Jane Liesveld, Adriana K Malone, Arnon Nagler, Seema Naik, Taiga Nishihori, Susan K Parsons, Angela Scherwath, Hannah-Lise Schofield, Robert Soiffer, Jeff Szer, Ida Twist, Anne Warwick, Baldeep M Wirk, Jean Yi, Minoo Battiwalla, Mary E Flowers, Bipin Savani, Bronwen E Shaw
Hematopoietic cell transplantation (HCT) is a potentially curative treatment for children and adults with malignant and nonmalignant diseases. Despite increasing survival rates, long-term morbidity after HCT is substantial. Neurocognitive dysfunction is a serious cause of morbidity, yet little is known about neurocognitive dysfunction after HCT. To address this gap, collaborative efforts of the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation undertook an expert review of neurocognitive dysfunction after HCT...
September 20, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28892084/validation-of-the-revised-ipss-at-transplant-in-patients-with-myelodysplastic-syndrome-transformed-acute-myelogenous-leukemia-receiving-allogeneic-stem-cell-transplantation-a-retrospective-analysis-of-the-ebmt-chronic-malignancies-working-party
#8
C Scheid, L de Wreede, A van Biezen, C Koenecke, G Göhring, L Volin, J Maertens, J Finke, J Passweg, D Beelen, J J Cornelissen, M Itälä-Remes, P Chevallier, N Russell, E Petersen, N Milpied, C Richard Espiga, A Peniket, J Sierra, G Mufti, C Crawley, J H Veelken, P Ljungman, J Y Cahn, E P Alessandrino, T de Witte, M Robin, N Kröger
The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate the use of the IPSS-R assessed before transplant rather than at diagnosis we performed a retrospective analysis of the EBMT database. A total of 579 patients had sufficient information available to calculate IPSS-R at transplant. Median overall survival (OS) from transplant was significantly different according to IPSS-R: very low 23.6 months, low 55...
November 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28807768/european-group-for-blood-and-marrow-transplantation-risk-score-predicts-the-outcome-of-patients-with-acute-leukemia-receiving-single-umbilical-cord-blood-transplantation
#9
Xiaoyu Zhu, Lulu Huang, Changcheng Zheng, Baolin Tang, Huilan Liu, Liangquan Geng, Juan Tong, Lei Zhang, Xuhan Zhang, Wen Yao, Kaidi Song, Xingbing Wang, Kaiyang Ding, Zimin Sun
The European Group for Blood and Marrow Transplantation (EBMT) risk score has been implemented as an important tool to predict patient outcomes after allogeneic hematopoietic stem cell transplantation. However, to our knowledge, this score has never been applied in cases of single umbilical cord blood transplantation (sUCBT). We retrospectively analyzed 207 consecutive patients with acute leukemia who received sUCBT at our center between February 2011 and December 2015. The probabilities of 3-year overall survival (OS) and leukemia-free survival (LFS) of the entire cohort were 65...
August 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28801752/biosimilar-g-csf-versus-filgrastim-and-lenograstim-in-healthy-unrelated-volunteer-hematopoietic-stem-cell-donors
#10
Roiya Farhan, Elżbieta Urbanowska, Hanna Zborowska, Małgorzata Król, Maria Król, Tigran Torosian, Iwona Piotrowska, Krzysztof Bogusz, Kamila Skwierawska, Wiesław Wiktor-Jędrzejczak, Emilian Snarski
The World Marrow Donor Organization recommends original granulocyte-colony stimulating factor (G-CSF) for the mobilization of stem cells in healthy unrelated hematopoietic stem cell donors. We report the comparison of a biosimilar G-CSF (Zarzio) with two original G-CSFs (filgrastim and lenograstim) in mobilization in unrelated donors. We included data of 313 consecutive donors who were mobilized during the period from October 2014 to March 2016 at the Medical University of Warsaw. The primary endpoints of this study were the efficiency of CD34+ cell mobilization to the circulation and results of the first apheresis...
October 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28797779/long-term-outcomes-of-cord-blood-transplantation-from-an-hla-identical-sibling-for-patients-with-bone-marrow-failure-syndromes-a-report-from-eurocord-cord-blood-committee-and-severe-aplastic-anemia-working-party-of-the-european-society-for-blood-and-marrow
#11
Simona Pagliuca, Régis Peffault de Latour, Fernanda Volt, Franco Locatelli, Marco Zecca, Jean-Hugues Dalle, Patrizia Comoli, Kim Vettenranta, Miguel Angel Diaz, Or Reuven, Yves Bertrand, Cristina Diaz de Heredia, Arnon Nagler, Ardeshir Ghavamzadeh, Sabina Sufliarska, Sarah Lawson, Chantal Kenzey, Vanderson Rocha, Carlo Dufour, Eliane Gluckman, Jakob Passweg, Annalisa Ruggeri
Cord blood transplantation (CBT) from HLA-identical siblings is an attractive option for patients with bone marrow failure (BMF) syndrome because of the low risk of graft-versus-host disease (GVHD) and the absence of risk to the donor. We analyzed outcomes of 117 patients with inherited or acquired BMF syndrome who received CBT from a related HLA-identical donor in European Society for Blood and Marrow Transplantation centers between 1988 and 2014. Ninety-seven patients had inherited and 20 patients acquired BMF syndrome...
August 7, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28751703/ebmt-nurses-group-poster-session
#12
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28751702/ebmt-lectures-1998-2017
#13
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28751700/ebmt-nurses-group-oral-sessions
#14
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28751697/ebmt-data-management-group-poster-session
#15
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28737775/fertility-preservation-issues-in-pediatric-hematopoietic-stem-cell-transplantation-practical-approaches-from-the-consensus-of-the-pediatric-diseases-working-party-of-the-ebmt-and-the-international-bfm-study-group
#16
A Balduzzi, J-H Dalle, K Jahnukainen, M von Wolff, G Lucchini, M Ifversen, K T Macklon, C Poirot, T Diesch, A Jarisch, D Bresters, I Yaniv, B Gibson, A M Willasch, R Fadini, L Ferrari, A Lawitschka, A Ahler, N Sänger, S Corbacioglu, M Ansari, R Moffat, A Dalissier, E Beohou, P Sedlacek, A Lankester, C D De Heredia Rubio, K Vettenranta, J Wachowiak, A Yesilipek, E Trigoso, T Klingebiel, C Peters, P Bader
Fertility preservation is an urgent challenge in the transplant setting. A panel of transplanters and fertility specialists within the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the International BFM Study Group provides specific guidelines. Patients and families should be informed of possible gender- and age-specific cryopreservation strategies that should be tailored according to the underlying disease, clinical condition and previous exposure to chemotherapy...
October 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28694085/baseline-characteristics-predicting-very-good-outcome-of-allogeneic-hematopoietic-cell-transplantation-in-young-patients-with-high-cytogenetic-risk-chronic-lymphocytic-leukemia%C3%A2-a-retrospective-analysis-from-the-chronic-malignancies-working-party-of-the-ebmt
#17
Michel van Gelder, Dimitris Ziagkos, Liesbeth de Wreede, Anja van Biezen, Peter Dreger, Martin Gramatzki, Matthias Stelljes, Niels Smedegaard Andersen, Nicolaas Schaap, Antonin Vitek, Dietrich Beelen, Vesa Lindström, Jürgen Finke, Jacob Passweg, Matthias Eder, Maciej Machaczka, Julio Delgado, William Krüger, Luděk Raida, Gerard Socié, Pavel Jindra, Boris Afanasyev, Eva Wagner, Yves Chalandon, Anja Henseler, Stefan Schoenland, Nicolaus Kröger, Johannes Schetelig
BACKGROUND: Patients with genetically high-risk relapsed/refractory chronic lymphocytic leukemia have shorter median progression-free survival (PFS) with kinase- and BCL2-inhibitors (KI, BCL2i). Allogeneic hematopoietic stem cell transplantation (alloHCT) may result in sustained PFS, especially in younger patients because of its age-dependent non-relapse mortality (NRM) risk, but outcome data are lacking for this population. PATIENTS AND METHODS: Risk factors for 2-year NRM and 8-year PFS were identified in patients < 50 years in an updated European Society for Blood and Marrow Transplantation registry cohort (n = 197; median follow-up, 90...
October 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28692024/no-report-on-zika-virus-infection-in-ebmt-registry-infectious-diseases-working-party-statement
#18
J Styczynski, J Hoek, N Knelange, M Mikulska, S Cesaro, M Aljurf, L Gil
No abstract text is available yet for this article.
September 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28687394/umbilical-cord-blood-cytomegalovirus-serostatus-does-not-have-an-impact-on-outcomes-of-umbilical-cord-blood-transplantation-for-acute-leukemia
#19
Olga Nikolajeva, Vanderson Rocha, Robert Danby, Annalisa Ruggeri, Fernanda Volt, Etienne Baudoux, Susana G Gomez, Gezine Kögler, Jerome Larghero, Lucilla Lecchi, Mar Sanchez Martinez, Cristina Navarrete, Fabienne Pouthiers, Sergio Querol, Chantal Kenzey, Richard Szydlo, Eliane Gluckman, Alejandro Madrigal
Several studies have reported an impact of adult hematopoietic stem cell donor cytomegalovirus (CMV) serostatus on allogeneic hematopoietic cell transplantation outcomes. Limited data, however, are available on the impact of cord blood unit (CBU) CMV serostatus on allogeneic umbilical cord blood transplantation (UCBT) outcomes. We analyzed, retrospectively, the impact of CBU CMV serostatus on relapse incidence (RI) and 2-year nonrelapse mortality (NRM) of single-unit CBU transplantation for acute leukemia. Data from 1177 de novo acute leukemia pediatric and adult patients transplanted within European Group for Blood and Marrow Transplantation centers between 2000 and 2012 were analyzed...
July 4, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28685597/invasive-fungal-infections-managing-the-continuum-of-risk-in-hct-patients
#20
Rafael F Duarte, Sue Lyon
43rd Annual Meeting of the EBMT, 26-29 March 2017, Marseille, France The European Society for Blood and Marrow Transplantation (EBMT) was established in 1974 to enable scientists and physicians to share their experience and develop studies in clinical bone marrow transplantation. Despite advances in treatment, invasive fungal infections (IFI), especially those caused by moulds such as Aspergillus, remain a leading cause of morbidity and mortality in patients with hematological malignancies. There is a continuum of risk of IFI during induction and consolidation therapy, and after hematopoietic cell transplantation...
August 2017: Future Microbiology
keyword
keyword
115198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"